{"id":685146,"date":"2022-09-14T08:33:40","date_gmt":"2022-09-14T12:33:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\/"},"modified":"2022-09-14T08:33:40","modified_gmt":"2022-09-14T12:33:40","slug":"sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\/","title":{"rendered":"SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference on September 28th"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, Sept.  14, 2022  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w5AV9yVcRbGmjhMQSSo3Z7QZ4lxKRjnO0CFSor5U-Elj4BTuIueiLuUjSEY4W80xXVjp9-9UTNob1xpIWqukAFNLgkcjXyEOiiODvKnZw1QQUkU5u4qz4ziIuAXb3B3eYEpr7nJQ1OHZra9rEft6bg==\" rel=\"nofollow noopener\" target=\"_blank\">SELLAS Life Sciences Group, Inc.<\/a>\u00a0(NASDAQ: SLS) (\u201cSELLAS\u2019\u2019 or the \u201cCompany\u201d), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD. h.c, President and Chief Executive Officer of SELLAS, will participate in the Cantor Oncology, Hematology, HemeOnc Conference to be held at the Lotte New York Palace in New York City on Wednesday, September 28, 2022.<\/p>\n<p>Dr. Stergiou will participate in the \u2018<em>Leukemia and MDS\u2019<\/em> panel at 3:25 p.m. Eastern Time.<\/p>\n<p>For more information about the conference, or to schedule a one-on-one meeting with SELLAS management, please contact your Cantor representative directly, or send an email to KCSA Strategic Communications at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w5AV9yVcRbGmjhMQSSo3Z-b-5wPnGxzsqLNEg5w2hedNGq5FIc6bszcVr25KKttkRAuV9e55EquuQQDbEYpYEw==\" rel=\"nofollow noopener\" target=\"_blank\">SELLAS@kcsa.com<\/a>.<\/p>\n<p>\n        <strong>About SELLAS Life Sciences Group, Inc.<\/strong><br \/>\n        <br \/>SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS\u2019 lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing GFH009, a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.<\/p>\n<p>For more information on SELLAS, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3OeVdoxCIQymyR6Ens5L0zwdBEVyA3oi4sxT7KIP6jOYnQ0Y4VXbfKEH0J8SCSbtll2zV8ZSo6yA-aQY52Gq92fuq_pyldBJ-C1B4IoHJaa51pDAi0yr0psLMvZXE7nExEAE9HQQrqpCLLOU58t9EA==\" rel=\"nofollow noopener\" target=\"_blank\">www.sellaslifesciences.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>\n        <em>Any statements in this press release or made during the investor conference referenced herein about SELLAS\u2019s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on the Company\u2019s clinical plans, risks and uncertainties associated with immune-oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption \u201cRisk Factors\u201d in SELLAS\u2019 Annual Report on Form 10-K filed on March 31, 2022 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS\u2019 forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.<\/em>\n      <\/p>\n<p>\n        <strong>Investor Contact <\/strong><br \/>\n        <br \/>Allison Soss <br \/>KCSA Strategic Communications <br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w5AV9yVcRbGmjhMQSSo3Z8_nLGBJdvOWdL6zZjNdCcFf4tX86xrtIz5ej9GoBeTdQS7cs_mdJeaymXJw0RKIow==\" rel=\"nofollow noopener\" target=\"_blank\">SELLAS@kcsa.com<\/a>\u00a0\u00a0 <br \/>Phone: 212.896.1267<\/p>\n<p>\n        <strong>Media Contact <\/strong><br \/>\n        <br \/>Raquel Cona \/ Michaela Fawcett<br \/>KCSA Strategic Communications <br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w5AV9yVcRbGmjhMQSSo3Z1DPx0jVb3PQMeVMr0Pk6aNEJgn_zi5icwEnUYcqReIkbRVFIpIQYjlysduL1Qu49Q==\" rel=\"nofollow noopener\" target=\"_blank\">SELLAS@kcsa.com<\/a>\u00a0\u00a0 <br \/>Phone: 212.896.1204<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjU1MiM1MTUxNTg0IzIxMjQzMjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NzdiZTI3OGUtNTdkZS00MWI4LTkwNjktYWM0NGRhNjQyN2IzLTExMzU4OTM=\/tiny\/SELLAS-Life-Sciences-Group-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Sept. 14, 2022 (GLOBE NEWSWIRE) &#8212; SELLAS Life Sciences Group, Inc.\u00a0(NASDAQ: SLS) (\u201cSELLAS\u2019\u2019 or the \u201cCompany\u201d), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD. h.c, President and Chief Executive Officer of SELLAS, will participate in the Cantor Oncology, Hematology, HemeOnc Conference to be held at the Lotte New York Palace in New York City on Wednesday, September 28, 2022. Dr. Stergiou will participate in the \u2018Leukemia and MDS\u2019 panel at 3:25 p.m. Eastern Time. For more information about the conference, or to schedule a one-on-one meeting with SELLAS management, please contact your Cantor representative directly, or send an email to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference on September 28th&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-685146","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference on September 28th - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference on September 28th - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Sept. 14, 2022 (GLOBE NEWSWIRE) &#8212; SELLAS Life Sciences Group, Inc.\u00a0(NASDAQ: SLS) (\u201cSELLAS\u2019\u2019 or the \u201cCompany\u201d), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD. h.c, President and Chief Executive Officer of SELLAS, will participate in the Cantor Oncology, Hematology, HemeOnc Conference to be held at the Lotte New York Palace in New York City on Wednesday, September 28, 2022. Dr. Stergiou will participate in the \u2018Leukemia and MDS\u2019 panel at 3:25 p.m. Eastern Time. For more information about the conference, or to schedule a one-on-one meeting with SELLAS management, please contact your Cantor representative directly, or send an email to &hellip; Continue reading &quot;SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference on September 28th&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-14T12:33:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjU1MiM1MTUxNTg0IzIxMjQzMjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference on September 28th\",\"datePublished\":\"2022-09-14T12:33:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\\\/\"},\"wordCount\":539,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0NjU1MiM1MTUxNTg0IzIxMjQzMjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\\\/\",\"name\":\"SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference on September 28th - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0NjU1MiM1MTUxNTg0IzIxMjQzMjI=\",\"datePublished\":\"2022-09-14T12:33:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0NjU1MiM1MTUxNTg0IzIxMjQzMjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0NjU1MiM1MTUxNTg0IzIxMjQzMjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference on September 28th\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference on September 28th - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\/","og_locale":"en_US","og_type":"article","og_title":"SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference on September 28th - Market Newsdesk","og_description":"NEW YORK, Sept. 14, 2022 (GLOBE NEWSWIRE) &#8212; SELLAS Life Sciences Group, Inc.\u00a0(NASDAQ: SLS) (\u201cSELLAS\u2019\u2019 or the \u201cCompany\u201d), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD. h.c, President and Chief Executive Officer of SELLAS, will participate in the Cantor Oncology, Hematology, HemeOnc Conference to be held at the Lotte New York Palace in New York City on Wednesday, September 28, 2022. Dr. Stergiou will participate in the \u2018Leukemia and MDS\u2019 panel at 3:25 p.m. Eastern Time. For more information about the conference, or to schedule a one-on-one meeting with SELLAS management, please contact your Cantor representative directly, or send an email to &hellip; Continue reading \"SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference on September 28th\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-14T12:33:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjU1MiM1MTUxNTg0IzIxMjQzMjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference on September 28th","datePublished":"2022-09-14T12:33:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\/"},"wordCount":539,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjU1MiM1MTUxNTg0IzIxMjQzMjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\/","name":"SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference on September 28th - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjU1MiM1MTUxNTg0IzIxMjQzMjI=","datePublished":"2022-09-14T12:33:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjU1MiM1MTUxNTg0IzIxMjQzMjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NjU1MiM1MTUxNTg0IzIxMjQzMjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference-on-september-28th\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference on September 28th"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/685146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=685146"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/685146\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=685146"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=685146"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=685146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}